This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Leonard R. Prosnitz, MD
Duke University Medical Center Durham, NC

JAMA. 1995;273(8):620.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Dr Cobleigh and colleagues¹ have done a fine job in reviewing the issues associated with the use of ERT in breast cancer survivors. Although the article is subtitled "A Time for Change," I looked in vain for a specific statement that the prescription of estrogens for women with a history of breast cancer and severe postmenopausal symptoms is justified. They clearly state that clinical trials are justified, but equally clearly the answers from such trials are at least 10 years away. Since one of the issues is medical-legal and since JAMA is an authoritative publication, I would ask Cobleigh and colleagues to indicate what they think is a reasonable position for clinicians to take until the definitive trials are available. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?